文摘
Summary
We retrospectively reviewed our clinical experience with PGB when used as add-on therapy in 101 patients (56 women and 45 men) with refractory partial epilepsy, who have been followed up for at least 1 year. Mean age was 40 years (16–64); mean number of concomitant AEDs was 2.8. Most patients (43) had temporal lobe epilepsy. Median number of seizures per month was 16 (3–240). Mean PGB dose used was 412.5 mg. Responder rate (percentage of patients with ≥50 % seizure reduction) at 6 and 12 months was 52 % and 39.6 % , respectively. Seizure freedom for at least 6 and 12 months has been achieved by 12 patients (11.8 % ) and 6 patients (5.9 % ) respectively. At 1 year, 61 patients (60.4 % ) are still taking PGB. Forty patients have discontinued PGB, because of inefficacy (16 patients, 15.8 % ), adverse effects (15 patients, 14.8 % ) or both (9 patients, 8.9 % ). Sixty per cent of patients reported adverse events, being weight gain (>10 % body weight) the most frequent, seen in 26 patients (25.7 % ). Dizziness/ataxia was seen in 20 (19.8 % ). Adverse effects were generally mild to moderate.
